Perspective

CLINICAL INVESTIGATION

Short note on cancer immunotherapy

Abstract

Cancer immunotherapy comprises the use of immunological agents such as cytokines, vaccines, cell treatments, and humoral, transfection agents to manipulate the immune system. The anti-tumor response of the host must be boosted by increasing the number of effector cells and soluble mediator production, while suppressor mechanisms must be lowered by creating a tumor-killing environment and modulating immunological checkpoints. Immunotherapy appears to work better in more immunogenic tumors. Bladder cancer was the initial indication for immunotherapy in 1970. Immune checkpoint inhibitors are a hot issue in bladder cancer clinical trials. Despite the notion that breast cancer is immunologically silent, several preclinical and clinical studies have shown that immunotherapy can improve breast cancer patients' clinical outcomes. Cervical cancer, brain cancer, head and neck cancer, colorectal cancer, and esophageal cancer are all getting new immune-based cancer treatments.

Submitted: 07 May 2021; Accepted: 21 May 2021; Published online: 28 May 2021

Christiana Williams*

Editorial Office, Clinical Investigation, London, UK

*Author for correspondence: clinicalinvestigation313@gmail.com

Introduction

BCG therapy for bladder cancer and Interferon's (IFN) therapy for malignant melanoma were the first cancer immunotherapies introduced in the 1970s. To treat solid tumors like melanoma, immunological therapies like the Interleukin-2 (IL2) cytokine have been created. Following that, these treatments began to fail, resulting in significant side effects and ineffective outcomes. There are cells involved in the immune response, mediators that influence immune response activation or inhibition, and the development of new therapies, in addition to examining immune response mechanisms.

Cancer immunotherapy includes the use of immunological agents such as cytokines, vaccines, cell treatments, and transfection agents to alter the immune system.

Cancer immunotherapy increases the number of effector cells and the synthesis of soluble mediators (such as increased tumor cell immunogenicity) while suppressing the host's suppressor mechanisms by generating tumor-killing settings and regulating immunological checkpoints. The most promising new cancer treatment strategy since the late 1940s, when the first chemotherapies were discovered, is cancer immunotherapy, which involves medications that strengthen the immune system's natural ability to attack cancer.

Immunotherapy appears to work better in more immunogenic tumors. The study addresses various novel immunologic treatments for tumors that have gotten less attention at recent conferences but for which immunotherapy is being investigated.

Bladder cancer was the first disease to be treated with immunotherapy in 1970. Other immune-based bladder cancer treatments are now in development. The majority of bladder cancers start in the transitional epithelial cells, which is called urothelial carcinoma.

Despite the fact that no new bladder cancer treatments have been produced, the overall 5-year survival rate for bladder cancer is 77%, with variations depending on the stage. This rate has remained consistent in recent years.

For non-muscle invasive bladder cancer, surgery is followed with intravesical chemotherapy, commonly Epirubicin, which is injected 8 hours following surgery. In patients with a low risk of disease development, surveillance or further intravesical chemotherapy may be utilized. In patients with moderate to high-grade disease, intravenous immunotherapy with Bacillus Calmette Guerin (BCG) is routinely employed. Patients with muscle-invasive bladder cancer are treated with cisplatin-based chemotherapy regimens, neoadjuvant administration followed by surgical excision of the bladder or radiation therapy, and concomitant chemotherapy, according to the guidelines. Recurrent and metastatic bladder cancer is treated with Methotrexate, Vinblastine, Doxorubicin, and Cisplatin

(MVAC) or Gemcitabine plus Cisplatin (GC), two chemotherapy regimens with similar response rates.

Immune checkpoint inhibitors are a promising clinical research issue in bladder cancer because they target molecules that function as checks in the regulation of immune responses and block inhibitory molecules or activate stimulatory molecules to augment pre-existing anti-cancer immune responses. Nivolumab, Ipilimumab, and Pertuzumab trials in metastatic bladder cancer are always looking for more volunteers.

Therapeutic vaccines stimulate the immune system to respond to antigens found only in tumors or antigens associated with tumors. Patients in phase II of the trial, which is currently enrolling patients with high-risk, non-muscle-invasive bladder cancer who have completed surgery, are receiving a therapeutic vaccine made from a human bladder cancer cell line that has been irradiated and engineered to express soluble gp96, a chaperone protein. In a phase I study, a fusion protein vaccine is being investigated in patients with a variety of solid tumors, including recurrent and metastatic bladder cancer, with or without the biological therapy sirolimus.

Cytokines are messenger molecules that contribute to the growth and function of immune system cells. Monoclonal antibodies are lab-created molecules that recognize antigens on cancerous cells. Combining the two looks to be an immunologically beneficial treatment. A combination of the cytokine Interleukin-2 (IL-2) and an antibody that recognizes peptides on the surface of tumor cells has been tested in clinical studies. By binding IL-2 to an antibody, ALT-801 can drive IL-2 to cancer cells, boosting the immune system's ability to combat cancer.

Oncolytic viral therapy uses a specially designed virus that causes tumor cells to self-destruct and release antigens, resulting in a greater immune response to cancer. The most well-known oncolytic virus is an oncolytic adenovirus that also expresses the immune-boosting cytokine Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF). This oncolytic adenovirus increases the anti-tumor immune response and is administered intravenously. Patients with CIS of the bladder or non-muscle invasive bladder cancer +CIS (Carcinoma In-Situ) of the bladder who have failed BCG therapy are being studied in phase II/III study.